Search

Made available in DSpace on 2013-08-12T17:58:55Z (GMT). No. of bitstreams: 0 Previous issue date: 2012-09-01 Made available in DSpace on 2013-09-30T18:20:09Z (GMT). No. of bitstreams: 0 Previous issue date: 2012-09-01 Submitted by Vitor Silverio Rodrigues (vitorsrodrigues@reitoria.unesp.br) on 2014-05-20T13:35:21Z No. of bitstreams: 1 WOS000309719800008.pdf: 182994 bytes, checksum: f67ace550f0fe880d2a7d27083247d88 (MD5) Made available in DSpace on 2014-05-20T13:35:21Z (GMT). No. of bitstreams: 1 WOS000309719800008.pdf: 182994 bytes, checksum: f67ace550f0fe880d2a7d27083247d88 (MD5) Previous issue date: 2012-09-01 The aim of this work was to evaluate the direct protective action of oral fatty acid supplementation against the deleterious effect of hyperglycemia on maternal reproductive outcomes; fetal growth and development on female Wistar rats. The animals were distributed into four experimental groups: G1= non-diabetic without supplementation (Control group); G2= non-diabetic treated with linoleic (LA) and gammalinolenic acid (GLA) (1 mL of Gamaline-V/day); G3= diabetic without supplementation and G4= diabetic treated with LA and GLA. Diabetes was induced by streptozotocin (40 mg/kg). At day 21 of pregnancy, the gravid uterus was weighed and dissected to count the dead and live fetuses, resorption, implantation, and corpora lutea numbers. The fetuses were analyzed for external and internal anomalies. The treatment with Gamaline-V supplementation to diabetic rats interfered in the maternal reproductive outcome (reduced number of live fetuses and embryonic implantation); however, it protected the deleterious on the incidence of congenital anomalies caused by hyperglycemia. Univ Estadual Paulista, Dept Ginecol & Obstet, Lab Pesquisa Expt Ginecol & Obstet, Botucatu, SP, Brazil Univ Estadual Paulista, Inst Biociencias, Dept Morfol, Botucatu, SP, Brazil Univ Fed Mato Grosso, Inst Ciencias Biol & Saude, Barra do Garcas, MT, Brazil Univ Estadual Paulista, Dept Ginecol & Obstet, Lab Pesquisa Expt Ginecol & Obstet, Botucatu, SP, Brazil Univ Estadual Paulista, Inst Biociencias, Dept Morfol, Botucatu, SP, Brazil

The aim of this study was to determine the consequent reproductive developmental and immunotoxic effects due to exposure to fenvalerate during pregnancy and lactation in male offspring of maternal-treated rats. Pregnant rats were treated daily by oral gavage with 40 or 80 mg/kg of fenvalerate or corn oil (vehicle, control), from d 12 of pregnancy to d 21 of lactation. Immune and reproductive developmental effects were assessed in male offspring at postnatal days (PND) 40 (peripuberty), 60 (postpuberty), and 90 (sexual maturity). Treatment with the higher dose (80 mg/kg) resulted in convulsive behavior, hyperexcitability, and mortality in 45% of the dams. Fenvalerate was detected in the fetus due to placental transfer, as well as in pups due to breast-milk ingestion, persisting in male offspring until PND 40 even though pesticide treatment was terminated on PND 20. However, fenvalerate did not produce marked alterations in age of testicular descent to the scrotum and prepucial separation, parameters indicative of puberty initiation. In contrast, at puberty, there was a reduction in testicular weight and sperm production in male offspring of maternal-treated rats. At adulthood, the sperm counts and fertility did not differ between control and treated groups. Testosterone levels were not changed at any time during reproductive development. Similarly, no apparent exposure-related effects were detected in the histological structures of the lymphohematopoietic system. Data indicate that fenvalerate, in this experimental model, interfered with initial development of the male reproductive system, but that these effects on sperm production or fertility did not persist into adulthood. There was no apparent evidence that fenvalerate altered testosterone levels or produced a disruption in male endocrine functions.

Background: Exposure of the spinal cord in myelomeningocele (MM) throughout gestation increases spinal injury. Astrocyte activation evidenced by glial fibrillary acidic proteins (GFAP) indicates the extent of injury. Corticosteroids modulate GFAP synthesis, but their effect in MM is unclear. The purpose of this study was to evaluate the GFAP expression in a fetal rat model of dysraphism and the effect of corticosteroid treatment on this marker and on clinical neurological disabilities. Methods: Dysraphism was surgically created in 2 groups of 48 rat fetuses; group 1: control, and group 2: treated with corticosteroid. Each group was subdivided into fetuses with surgically created MM, controls and shams on day 18.5 of gestation (term = 22 days). Fetuses were harvested on day 21.5, examined for evidence of neurological deficits, and the following clinical parameters were registered: kyphosis, tail deformities, leg deformities, leg paralysis or paresis and pain perception. The fetuses were fixed for GFAP immunostaining. Results: All fetuses with MM in group 1 presented neurological deficits and glial reactions with GFAP expression, as opposed to controls and shams. In group 2, corticosteroid treatment prevented some neurological deficits (18–25%), reducing glial response and GFAP expression. Conclusions: Experimentally induced dysraphism in the rat fetus is related to glial response and increased GFAP expression in the spinal cord. Corticoid treatment clinically improved nerve injury in some fetuses. It reduced glial reaction and GFAP expression.

Orientador: Lourenço Sbragia Neto Tese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciencias Medicas Resumo: A Hérnia Diafragmática Congênita (HDC) é um defeito da formação do músculo diafragma que incide em aproximadamente 1:2500 nascidos vivos e apresenta altos índices de mortalidade fetal e neonatal decorrentes da hipoplasia e da hipertensão pulmonares. Este defeito pode ser induzido experimentalmente em ratas grávidas administrando o herbicida nitrofen que causa HDC em 24% dos fetos. A análise microscópica do pulmão da HDC demonstra a presença de hipolasia pulmonar além de alveolização e vascularização alterada. Um dos fatores de crescimento envolvidos no desenvolvimento vascular é o VEGF (vascular endothelial growth factor) e seus receptores, no entanto ainda não se conhece como a expressão desta glicoproteína e de seus receptores varia ao longo do desenvolvimento pulmonar fetal nesta doença. Utilizando o modelo experimental de HDC induzido pelo nitrofen (2,4-dicloro-4'nitrodifenil éter) investigamos o grau de hipoplasia pulmonar e por meio de análise imunoistoquímica, comparamos a expressão dos receptores para o VEGF em três fases do desenvolvimento pulmonar, pseudoglandular, canalicular e sacular de fetos de ratos normais e com HDC. Dividimos o experimento em ratas da raça Sprague-Dawley em três grupos: controle externo (CE), exposto ao óleo de oliva (OO) e expostas ao nitrofen com e sem HDC. Estudamos quatro grupos de 20 fetos cada em cinco dias gestacionais (DG) diferentes 17,5, 18,5, 19,5, 20,5 e 21,5. As variáveis morfológicas estudadas foram: peso corporal (PC), peso pulmonar total (PPT), peso do pulmão esquerdo (PPE), relação PPT/PC, volume pulmonar total (VPT) e volume do pulmão esquerdo (VPE). As variáveis histométricas estudadas foram: parênquima pulmonar (Par), espaço aéreo (EA), densidade do parênquima (DAP) e volume do parênquima do pulmão esquerdo. A avaliação imumohistoquímica foi realizada por meio da contagem de pontos de receptor de VEGFR-1 e 2. Obtivemos 37 % (100/270) de HDC nas ratas expostas ao nitrofen, todas variáveis morfológicas e histométricas indicam diminuição dos resultados no grupo nitrofen com e sem HDC em relação aos demais, mas que se acentuam mais ainda no grupo HDC. Essas alterações são mais evidentes a partir dos DG 18,5 e 19,5. A imunomarcação para os receptores VEGFR-1 aumentou nos grupos nitrofen e foram progressivamente maiores no grupo nitrofen com HDC (p

Investigate the effects of antenatal steroids and tracheal occlusion on pulmonary expression of vascular endothelial growth factor receptors in rats with nitrofen-induced congenital diaphragmatic hernia.Fetuses were exposed to nitrofen at embryonic day 9.5. Subgroups received dexamethasone or were operated on for tracheal occlusion, or received combined treatment. Morphologic variables were recorded. To analyze vascular endothelial growth factor receptor 1 and vascular endothelial growth factor receptor 2 expression, we performed Western blotting and immunohistochemistry. Morphologic variables were analyzed by analysis of variance and immunohistochemistry by Kruskal-Wallis test.Congenital diaphragmatic hernia decreased body weight, total lung weight, and lung-to-body weight ratio. Tracheal occlusion increased total lung weight and lung-to-body weight ratio (P.05). Fetuses with congenital diaphragmatic hernia had reduced vascular endothelial growth factor receptor 1 and vascular endothelial growth factor receptor 2 expression, whereas steroids and tracheal occlusion increased their expression. Combined treatment increased expression of receptors, but had no additive effect.Vascular endothelial growth factor signaling disruption may be associated with pulmonary hypertension in congenital diaphragmatic hernia. Tracheal occlusion and steroids provide a pathway for restoring expression of vascular endothelial growth factor receptors.